Neumora Therapeutics (NMRA) Operating Leases (2022 - 2026)

Neumora Therapeutics has reported Operating Leases for 5 years, with the latest figure at $119000.0 in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases changed N/A year-over-year to $119000.0; the trailing twelve-month figure through Mar 2026 stood at $119000.0 (changed N/A YoY), and the FY2025 full-year result was $193000.0, changed N/A from the prior year.
• Operating Leases for Q1 2026 stood at $119000.0, down from $193000.0 in the prior quarter.
• The five-year high for Operating Leases was $5.1 million in Q4 2022, with the low at $119000.0 in Q1 2026.
• Average Operating Leases over 5 years is $1.4 million, with a median of $638500.0 recorded in 2024.
• Peak annual rise in Operating Leases reached 63.47% in 2023, while the deepest fall reached 63.47% in 2023.
• Tracing NMRA's Operating Leases over 5 years: stood at $5.1 million in 2022, then slumped by 63.47% to $1.9 million in 2023, then tumbled by 49.38% to $938000.0 in 2024, then slumped by 79.42% to $193000.0 in 2025, then sank by 38.34% to $119000.0 in 2026.
• The last three Operating Leases figures came in at $119000.0 (Q1 2026), $193000.0 (Q4 2025), and $267000.0 (Q3 2025), per Business Quant data.

Peer Comparison